SEARCHCROSS-SECTIONALcardiology, internal medicine

cross-sectional·cardiology, internal medicine, epidemiology, geriatrics·PMC10047835

Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis

Diseases · 6 authors, 3 centres

AI SUMMARY

FIDELITY 100%

POPULATION250 patients (mean age 69 ± 3 years, 42% males) divided into groups with calcific aortic valve stenosis (CAVS) with or without coronary heart disease (CHD) and a control group.

INTERVENTIONMeasurement of lipoprotein(a) [Lp(a)] and IgM autoantibodies to oxidized Lp(a) [oxLp(a)].

COMPARISONComparison between patients with CAVS (with/without CHD) and a control group without CAVS or CHD.

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This cross-sectional, single-center study assessed Lp(a) and IgM autoantibodies to oxLp(a) in 250 patients with and without CAVS and CHD.

Full summary

622 CHARS

This cross-sectional, single-center study assessed Lp(a) and IgM autoantibodies to oxLp(a) in 250 patients with and without CAVS and CHD. Diagnosis of CAVS was based on echocardiography criteria, and CHD was confirmed by coronary angiography. Logistic regression analysis identified age, higher Lp(a) levels, and lower IgM autoAbs to oxLp(a) as independent predictors of CAVS. A concomitant Lp(a) level ≥30 mg/dL and IgM autoAbs <9.9 lab. units were strongly associated with CAVS (OR 6.4) and with CAVS plus CHD (OR 17.3). The study's limitations include its small cohort size and potential age differences between groups.

PICO

PPOPULATION

250 patients (mean age 69 ± 3 years, 42% males) divided into groups with calcific aortic valve stenosis (CAVS) with or without coronary heart disease (CHD) and a control group.

IINTERVENTION

Measurement of lipoprotein(a) [Lp(a)] and IgM autoantibodies to oxidized Lp(a) [oxLp(a)].

OOUTCOME

Presence of calcific aortic valve stenosis (CAVS).

STUDY TYPE

cross-sectional

SPECIALTY

cardiology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10047835

Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis

Diseases

READ THE FULL PAPER

ABSTRACT

Aortic valve stenosis is the most common valvular heart disease in the Western world. Lipoprotein(a) (Lp(a)) is an independent risk factor of coronary heart disease (CHD) and calcific aortic valve stenosis (CAVS). The aim of this study was to assess the role of Lp(a) and its autoantibodies [autoAbs] in CAVS in patients with and without CHD. We included 250 patients (mean age 69 ± 3 years, males 42%) and divided them into three groups. There were two groups of patients with CAVS depending on the presence (group 1) or absence of CHD (group 2). The control group included the patients without CHD or CAVS. According to logistic regression analysis, levels of Lp(a), IgM autoAbs to oxidized Lp(a) (oxLp(a)), and age were independent predictors of CAVS. A concomitant increase in Lp(a) level (≥30 mg/dL) and a decrease in IgM autoAbs concentration (<9.9 lab. Units) are associated with CAVS with an odds ratio (OR) of 6.4, p < 0.01, and with CAVS and CHD with an OR of 17.3, p < 0.001. IgM autoantibodies to oxLp(a) are associated with calcific aortic valve stenosis regardless of Lp(a) concentration and other risk factors. Higher Lp(a) and lower IgM autoantibodies to oxLp(a) levels are associated with a much higher risk of calcific aortic valve stenosis.

CITATION EXPORT

Anna L. Burdeynaya, Olga I. Afanasieva, Marat V. Ezhov et al.. Lipoprotein(a) and Its Autoantibodies in Association with Calcific Aortic Valve Stenosis. Diseases. (2023). https://doi.org/10.3390/diseases11010043

AUTHORS

6 · 3 CENTRES

Anna L. Burdeynaya, Olga I. Afanasieva, Marat V. Ezhov, Elena A. Klesareva, Marina A. Saidova, Sergey N. Pokrovsky

1Laboratory of Lipid Disorders, Department of Atherosclerosis, A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia
2Laboratory of Atherosclerosis, Institute of Experimental Cardiology Named after Academician V.N. Smirnov, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia
3Department of Ultrasound Diagnostics, A.L. Myasnikov Institute of Clinical Cardiology, Federal State Budgetary Institution National Medical Research Center of Cardiology Named after Academician E.I. Chazov, Ministry of Health of the Russian Federation, 121552 Moscow, Russia

EDITOR / REVIEWER

Chim C. Lang